肠易激综合征治疗与预防的研究进展

doi:10.12114/j.issn.1007-9572.2021.02.138

摘要/Abstract

摘要： 肠易激综合征（IBS）是一种胃肠道功能紊乱的慢性疾病，临床症状主要有腹痛和排便异常，临床上将IBS分为4种类型，环境因素和宿主差异是导致IBS的原因，但确切发病机制尚不清楚。IBS的诊断、治疗和预防在临床上均较棘手，需要针对患者的生理和心理采用个性化的治疗方法，具体包括专业指导、饮食干预和心理疏导等。IBS不同于功能性腹泻和功能性便秘的最主要诊断要点为腹痛，治疗方法包括非药物疗法和/或药物疗法，总体来说，IBS的药物治疗主要根据患者的具体情况而定。新进研究表明，肠道菌群也参与了IBS的发生发展，通过使用益生菌以及肠道微生物群移植可能成为治疗IBS的有效措施。本文综述了IBS发生发展的最新机制、目前的治疗方法、预防策略以及未来可能的研究方向。

关键词: 肠易激综合征, 体征和症状, 诊断, 治疗, 综合预防

Abstract:

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disease. The clinical symptoms of IBS mainly include abdominal pain and abnormal bowel movements. Clinically, IBS is divided into four types, which are caused by environmental and host factors, but the exact pathogenesis is unclear. Clinical diagnosis, treatment, and prevention of IBS are rather tricky. In contrast to functional diarrhea and constipation, the most notable symptom for diagnosing IBS is abdominal pain. The treatments for IBS include non-drug treatment and/or drug treatment. In general, the non-drug treatment is delivered in accordance with the patient's physiology and psychology, including professional guidance, dietary intervention, and psychological counseling. And drug treatment is implemented depending on the specific condition of the patient. Recent studies have shown that the intestinal flora is also involved in the incidence and progression of IBS, and the use of probiotics and intestinal microbiota transplantation may be effective treatments for IBS. This article reviews the latest developments in pathogenesis, treatments, prevention strategies, and possible future research directions regarding IBS.

Key words: Irritable bowel syndrome, Signs and symptoms, Diagnosis, Therapy, Universal precautions

中图分类号:

R574.62

高炼,黄晓明,吴清明. 肠易激综合征治疗与预防的研究进展[J]. 中国全科医学, 2022, 25(09): 1148-1154. DOI: 10.12114/j.issn.1007-9572.2021.02.138.

GAO Lian, HUANG Xiaoming, WU Qingming.

Recent Developments in the Prevention and Treatment of Irritable Bowel Syndrome [J]. Chinese General Practice, 2022, 25(09): 1148-1154.

参考文献 59

[1]	胡玥，吕宾. 肠易激综合征的治疗进展[J]. 中国实用内科杂志，2020，40(2):105-110. DOI：10.19538/j.nk2020020105.
[2]	FORD A C，SPERBER A D，CORSETTI M，et al. Irritable bowel syndrome[J]. Lancet，2020，396(10263):1675-1688. DOI：10.1016/S0140-6736(20)31548-8.
[3]	WILEY J W，CHANG L. Functional bowel disorders[J]. Gastroenterology，2018，155(1):1-4. DOI：10.1053/j.gastro.2018.02.014.
[4]	李彦楠，杨丽旋，赵钟辉，等. 《2020年中国肠易激综合征专家共识意见》解读[J]. 中国临床医生杂志，2021，49(10):1151-1155.
[5]	OSTERTAG D，BUHNER S，MICHEL K，et al. Reduced responses of submucous neurons from irritable bowel syndrome patients to a cocktail containing histamine，serotonin，TNFα，and tryptase （IBS-cocktail）[J]. Front Neurosci，2015，9:465. DOI：10.3389/fnins.2015.00465.
[6]	TÖRNBLOM H，DROSSMAN D A. Psychopharmacologic therapies for irritable bowel syndrome[J]. Gastroenterol Clin N Am，2021，50(3):655-669. DOI：10.1016/j.gtc.2021.04.005.
[7]	詹胜刚，王立生. 应激和肠道菌群在肠易激综合征内脏疼痛中的机制研究[J]. 中国微生态学杂志，2017，29(1):122-125. DOI：10.13381/j.cnki.cjm.201701030.
[8]	EOM S，LEE J，BAEK Y B，et al. Identification and molecular study on the interaction of Schisandrin C with human 5-HT3A receptor[J]. Eur J Pharmacol，2021，906:174220. DOI：10.1016/j.ejphar.2021.174220.
[9]	SCIAVILLA P，STRATI F，DI PAOLA M，et al. Gut microbiota profiles and characterization of cultivable fungal isolates in IBS patients[J]. Appl Microbiol Biotechnol，2021，105(8):3277-3288. DOI：10.1007/s00253-021-11264-4.
[10]	TRAINI C，IDRIZAJ E，GARELLA R，et al. Otilonium Bromide treatment prevents nitrergic functional and morphological changes caused by chronic stress in the distal colon of a rat IBS model[J]. J Cell Mol Med，2021，25(14):6988-7000. DOI：10.1111/jcmm.16710.
[11]	周长丽. 罗马Ⅳ标准下肠易激综合征相关风险因素及运动干预的实证研究[D]. 长春：吉林大学，2019.
[12]	NG Q X，SOH A Y S，LOKE W，et al. The role of inflammation in irritable bowel syndrome （IBS）[J]. J Inflamm Res，2018，11:345-349. DOI：10.2147/jir.s174982.
[13]	CARUSO C，COLANTUONO S，CELI G，et al. Modulation of gut microbiota in patients with IBS and systemic nickel allergy after diet and probiotic supplementation：a pilot study[J]. J Biol Regul Homeost Agents，2020，34(5):1929-1934. DOI：10.23812/20-162-l.
[14]	WANG B，ZHAO W，ZHAO C S，et al. What impact do Rome IV criteria have on patients with IBS in China?[J]. Scand J Gastroenterol，2019，54(12):1433-1440. DOI：10.1080/00365521.2019.1698650.
[15]	AZIZ I，TÖRNBLOM H，PALSSON O S，et al. How the change in IBS criteria from RomeⅢ to RomeⅣ impacts on clinical characteristics and key pathophysiological factors[J]. Am J Gastroenterol，2018，113(7):1017-1025. DOI：10.1038/s41395-018-0074-z.
[16]	VASANT D H，PAINE P A，BLACK C J，et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome[J]. Gut，2021，70(7):1214-1240. DOI：10.1136/gutjnl-2021-324598.
[17]	WILLIAMS J，MILLS M T，WARRINER D R. Implications of the 2021 National Institute for Health and Care Excellence atrial fibrillation guidelines[J]. Br J Hosp Med （Lond），2021，82(9):1-4. DOI：10.12968/hmed.2021.0419.
[18]	ORLANDO A，TUTINO V，NOTARNICOLA M，et al. Improved symptom profiles and minimal inflammation in IBS-D patients undergoing a long-term low-FODMAP diet：a lipidomic perspective[J]. Nutrients，2020，12(6):1652. DOI：10.3390/nu12061652.
[19]	PICARELLI A，GRECO N，SCIUTTINI F，et al. High consumption of Nickel-containing foods and IBS-like disorders：late events in a gluten-free diet[J]. Ecotoxicol Environ Saf，2021，222:112492. DOI：10.1016/j.ecoenv.2021.112492.
[20]	ALTOMARE A，DI ROSA C，IMPERIA E，et al. Diarrhea predominant-irritable bowel syndrome （IBS-D）：effects of different nutritional patterns on intestinal dysbiosis and symptoms[J]. Nutrients，2021，13(5):1506. DOI：10.3390/nu13051506.
[21]	赵爱华. 心理护理干预在肠易激综合征治疗中的应用[J]. 世界最新医学信息文摘，2017，17(2):288,292. DOI：10.19613/j.cnki.1671-3141.2017.102.162.
[22]	LINDFORS P，UNGE P，ARVIDSSON P，et al. Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized，controlled trials[J]. Am J Gastroenterol，2012，107(2):276-285. DOI：10.1038/ajg.2011.340.
[23]	徐桂兴，黄碧清，熊俊. 针灸治疗肠易激综合征的系统评价[J]. 中华中医药学刊，2016，34(9):2171-2174. DOI：10.13193/j.issn.1673-7717.2016.09.035.
[24]	PEI L，CHEN H，GUO J，et al. Effect of acupuncture and its influence on visceral hypersensitivity in IBS-D patients：Study protocol for a randomized controlled trial[J]. Medicine：Baltimore，2018，97(21):e10877. DOI：10.1097/md.0000000000010877.
[25]	ZHENG H，JIN S，SHEN Y L，et al. Chinese herbal medicine for irritable bowel syndrome：a meta-analysis and trial sequential analysis of randomized controlled trials[J]. Front Pharmacol，2021，12:694741. DOI：10.3389/fphar.2021.694741.
[26]	CARRASCO-LABRA A，LYTVYN L，FALCK-YTTER Y，et al. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults （IBS-D）[J]. Gastroenterology，2019，157(3):859-880. DOI：10.1053/j.gastro.2019.06.014.
[27]	韩伟，赵丽，周金池，等. 利福昔明在胃肠道疾病中的应用现状[J]. 胃肠病学和肝病学杂志，2020，29(4):466-468,473.
[28]	HOU Q K，ZHU S L，ZHANG C R，et al. Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice[J]. Biomedecine Pharmacother，2019，118:109206. DOI：10.1016/j.biopha.2019.109206.
[29]	赖步洪，吴荣伟，黄金水. 奥替溴铵联合洛哌丁胺治疗改善腹泻型肠易激综合征患者症状及生活质量效果分析[J]. 内科，2017，12(6):798-800. DOI：10.16121/j.cnki.cn45-1347/r.2017.06.23.
[30]	LI X，LI B，ZHANG J，et al. Efficacy of opioid receptor modulators in patients with irritable bowel syndrome：a systematic review and meta-analysis[J]. Medicine：Baltimore，2021，100(4):e24361. DOI：10.1097/md.0000000000024361.
[31]	LEMBO A J，COVINGTON P S，DOVE L S，et al. Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D：Additional post hoc analyses of Phase 3 trials[J]. Neurogastroenterol Motil，2020，32(4):e13774. DOI：10.1111/nmo.13774.
[32]	LACY B E，HARRIS L A，CHANG L，et al. Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D：a subgroup analysis of phaseⅢtrials[J]. Therap Adv Gastroenterol，2019，12:1756284819841290. DOI：10.1177/1756284819841290.
[33]	CARRASCO-LABRA A，LYTVYN L，FALCK-YTTER Y，et al. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults （IBS-D）[J]. Gastroenterology，2019，157(3):859-880. DOI：10.1053/j.gastro.2019.06.014.
[34]	林懋惺，杨丽. 5-HT受体与肠易激综合征[J].医学综述，2007，13(5):398-400.
[35]	CHEN Y，CHU F，LIN J，et al. The mechanisms of action of WeiChang'An Pill （WCAP） treat diarrhoea-predominant irritable bowel syndrome （IBS-D） using network pharmacology approach and in vivo studies[J]. J Ethnopharmacol，2021，275:114119. DOI：10.1016/j.jep.2021.114119.
[36]	TAYLOR D C A，ABEL J L，MARTIN C，et al. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data：the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform （CONTOR）[J]. J Med Econ，2020，23(10):1072-1083. DOI：10.1080/13696998.2020.1799816.
[37]	VU V，FARKAS C，RIYAD O，et al. Enhancement of the enzymatic hydrolysis efficiency of wheat bran using the Bacillus strains and their consortium[J]. Bioresour Technol，2022，343:126092. DOI：10.1016/j.biortech.2021.126092.
[38]	李保亚. 马来酸曲美布汀胶囊联合聚乙二醇4000散口服治疗便秘型肠易激综合征的临床疗效[J]. 中国肛肠病杂志，2019，39(5):36-37.
[39]	雷云霞，蔡淦. 5羟色胺在肠易激综合征中的作用[J]. 中国中西医结合消化杂志，2005，13(6):410-413.
[40]	CAMILLERI M，BOECKXSTAENS G. Dietary and pharmacological treatment of abdominal pain in IBS[J]. Gut，2017，66(5):966-974. DOI：10.1136/gutjnl-2016-313425.
[41]	曾之晅，汪欢，杨新，鞥.肠易激综合征治疗研究进展[J].中华内科杂志，2017，56(2):140-143. DOI：CNKI:SUN:ZHNK.0.2017-02-022.
[42]	邹多武.利那洛肽：慢性便秘和便秘型肠易激综合征的新选择[J].中华消化杂志，2019，39(4):286-288. DOI：10.3760/cma.j.issn.0254-1432.2019.04.016.42.
[43]	ZHAO Q F，YONG F Y，YAN C，et al. Effects of linaclotide in the treatment of chronic constipation and irritable bowel syndrome with constipation：a meta-analysis[J]. Z Gastroenterol，2021，7(26):2-8. DOI：10.1055/a-1491-1784
[44]	HENSTRÖM M，HADIZADEH F，BEYDER A，et al. TRPM8 polymorphisms associated with increased risk of IBS-C and IBS-M[J]. Gut，2017，66(9):1725-1727. DOI：10.1136/gutjnl-2016-313346.
[45]	李媛. 腹泻型、便秘型以及混合型肠易激综合征患者肠道菌群的差异性比较[J]. 世界最新医学信息文摘，2018，18(46):61-62. DOI：10.19613/j.cnki.1671-3141.2018.46.034.
[46]	FASSOV J，LUNDBY L，LAURBERG S，et al. Three-year follow-up of sacral nerve stimulation for patients with diarrhoea-predominant and mixed irritable bowel syndrome[J]. Colorectal Dis，2017，19(2):188-193. DOI：10.1111/codi.13428.
[47]	BLACK C J，YUAN Y H，SELINGER C P，et al. Efficacy of soluble fibre，antispasmodic drugs，and gut-brain neuromodulators in irritable bowel syndrome：a systematic review and network meta-analysis[J]. Lancet Gastroenterol Hepatol，2020，5(2):117-131. DOI：10.1016/S2468-1253(19)30324-3.
[48]	王彬，赵威，晋弘，等. 薄荷油治疗肠易激综合征的基础和临床研究进展[J]. 胃肠病学，2017，22(2):118-120.
[49]	HUSSAIN Z，JUNG D H，LEE Y J，et al. The effect of trimebutine on the overlap syndrome model of Guinea pigs[J]. J Neurogastroenterol Motil，2018，24(4):669-675. DOI：10.5056/jnm18049.
[50]	GETACHEW B，AUBEE J I，SCHOTTENFELD R S，et al. Ketamine interactions with gut-microbiota in rats：relevance to its antidepressant and anti-inflammatory properties[J]. BMC Microbiol，2018，18(1):222. DOI：10.1186/s12866-018-1373-7.
[51]	GUNN D，GARSED K，LAM C，et al. Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron[J]. Aliment Pharmacol Ther，2019，50(5):538-546. DOI：10.1111/apt.15420.
[52]	ZAH V，IMRO M，TATOVIC S，et al. Concomitant use of benzodiazepines in chronic pain patients adherent to extended-release tapentadol or oxycodone treatment——a retrospective claims analysis[J]. J Opioid Manag，2020，16(6):461-479. DOI：10.5055/jom.2020.0604.
[53]	RAY K. Yeast probiotics for the treatment of IBD[J]. Nat Rev Gastroenterol Hepatol，2021，18(9):594. DOI：10.1038/s41575-021-00497-3.
[54]	尹泉，肖文，赵超，等. 益生菌治疗腹泻型肠易激综合征患者的疗效及对肠道菌群的影响[J]. 深圳中西医结合杂志，2021，31(11):154-156. DOI：10.16458/j.cnki.1007-0893.2021.11.071.
[55]	WEN Y，LI J，LONG Q，et al. The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome：a systematic review and meta-analysis based on seventeen randomized controlled trials[J]. Int J Surg，2020，79:111-119. DOI：10.1016/j.ijsu.2020.04.063.
[56]	EL-SALHY M，KRISTOFFERSEN A B，VALEUR J，et al. Long-term effects of fecal microbiota transplantation （FMT） in patients with irritable bowel syndrome[J]. Neurogastroenterol Motil，2021:e14200. DOI：10.1111/nmo.14200.
[57]	EL-SALHY M，HAUSKEN T，HATLEBAKK J G. Increasing the dose and/or repeating faecal microbiota transplantation （FMT） increases the response in patients with irritable bowel syndrome （IBS）[J]. Nutrients，2019，11(6):E1415. DOI：10.3390/nu11061415.
[58]	TABONE M，BRESSA C，GARCÍA-MERINO J A，et al. The effect of acute moderate-intensity exercise on the serum and fecal metabolomes and the gut microbiota of cross-country endurance Athletes[J]. Sci Rep，2021，11(1):3558. DOI：10.1038/s41598-021-82947-1.
[59]	HUNT M，MIGUEZ S，DUKAS B，et al. Efficacy of zemedy，a mobile digital therapeutic for the self-management of irritable bowel syndrome：crossover randomized controlled trial[J]. JMIR Mhealth Uhealth，2021，9(5):e26152. DOI：10.2196/26152.